Brain gliomas' variable growth patterns and locations hinder complete surgical removal, while existing clinical imaging/histological methods fail to guide intraoperative resection. To address this, we developed blue-green dual-color probes (perovskite quantum dots conjugated to antibodies) targeting glioma cells and IDH1-mutant simultaneously. These enable rapid intraoperative in vitro pathological diagnosis, helping surgeons devise resection strategies for personalized precise treatment. Tested on 56 clinical frozen sections, the combined detection using dual probes can be completed within 30 min with 91% accuracy: the glioma-targeting probe identifies tumor boundaries, while the IDH1-targeting one distinguishes subtypes for optimized margin delineation. We established a personalized resection strategy guided by these results; the dual-target probes show great potential to assist neurosurgeons in precise glioma resection.
Wu et al. (Mon,) studied this question.